Health care stocks were lower Monday afternoon, with the NYSE Health Care Index easing 0.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.3%.
The iShares Biotechnology ETF (IBB) shed 0.2%.
In corporate news, AbbVie (ABBV) shares tumbled 12%. The company said its two phase 2 trials assessing emraclidine in adult patients with schizophrenia and acute exacerbation of psychotic symptoms failed to meet their primary goal.
Cigna (CI) shares climbed past 7%. The health insurer said it's not pursuing a combination with Humana (HUM) and is on track to meet its full-year earnings target. Humana shares fell almost 2%.
Novavax (NVAX) said Monday that the US Food and Drug Administration has lifted a clinical hold on an investigational new-drug application for its Covid-Influenza combination and stand-alone flu vaccine candidates. Its shares popped 2%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.